首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Rational Development Of High-affinity T-cell Receptor-like Antibodies
【24h】

Rational Development Of High-affinity T-cell Receptor-like Antibodies

机译:高亲和力T细胞受体样抗体的合理开发

获取原文
获取原文并翻译 | 示例
           

摘要

T-cell interaction with a target cell is a key event in the adaptive immune response and primarily driven by T-cell receptor (TCR) recognition of peptide-MHC (pMHC) complexes. TCR avidity for a given pMHC is determined by number of MHC molecules, availability of coreceptors, and TCR affinity for MHC or peptide, respectively, with peptide recognition being the most important factor to confer target specificity. Here we present high-resolution crystal structures of 2 Fab antibodies in complex with the immunodomi-nant NY-ESO-1_(157-165) peptide analogue (SLLMWITQV) presented by HLA-A*0201 and compare them with a TCR recognizing the same pMHC. Binding to the central methionine-tryptophan peptide motif and orientation of binding were almost identical for Fabs and TCR. As the MW "peg" dominates the contacts between Fab and peptide, we estimated the contributions of individual amino acids between the Fab and peptide to provide the rational basis for a peptide-focused second-generation, high-affinity antibody library. The final Fab candidate achieved better peptide binding by 2 light-chain mutations, giving a 20-fold affinity improvement to 2-4 nM, exceeding the affinity of the TCR by 1,000-fold. The high-affinity Fab when grafted as recombinant TCR on T cells conferred specific killing of HLA-A*0201/NY-ESO-1_(157-165) target cells. In summary, we prove that affinity maturation of antibodies mimicking a TCR is possible and provide a strategy for engineering high-affinity antibodies that can be used in targeting specific pMHC complexes for diagnostic and therapeutic purposes.rnantibody engineering; crystallography; tumor immunology
机译:T细胞与靶细胞的相互作用是适应性免疫反应中的关键事件,并且主要由肽MHC(pMHC)复合物的T细胞受体(TCR)识别驱动。给定pMHC的TCR亲和力分别取决于MHC分子的数量,共受体的可用性以及对MHC或肽的TCR亲和力,其中肽的识别是赋予靶标特异性的最重要因素。在这里,我们提出了由HLA-A * 0201提出的与免疫力强的NY-ESO-1_(157-165)肽类似物(SLLMWITQV)配合使用的2种Fab抗体的高分辨率晶体结构,并将它们与识别相同抗体的TCR进行比较pMHC。对于Fab和TCR,与中央蛋氨酸-色氨酸肽基序的结合和结合方向几乎相同。由于MW“ peg”支配Fab与肽之间的接触,我们估算了Fab与肽之间各个氨基酸的贡献,从而为以肽为重点的第二代高亲和力抗体库提供了合理的基础。最终的Fab候选物通过2个轻链突变实现了更好的肽结合,亲和力提高了20倍,达到2-4 nM,超过了TCR的亲和力1000倍。高亲和力Fab作为重组TCR移植到T细胞上时,可特异性杀死HLA-A * 0201 / NY-ESO-1_(157-165)靶细胞。总而言之,我们证明了模仿TCR的抗体的亲和力成熟是可能的,并提供了一种工程化高亲和力抗体的策略,该抗体可用于靶向特异性pMHC复合物以用于诊断和治疗目的。晶体学肿瘤免疫学

著录项

  • 来源
  • 作者单位

    Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford 0X3 9DS, United Kingdom;

    Department of Oncology, University Hospital Zurich, CH-8091 Zurich, Switzerland;

    Centre for Molecular Medicine and Klinik I fur Innere Medizin, Labor Tumorgenetik, Universitat zu Kbln, 50924 Cologne, Germany;

    Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford 0X3 9DS, United Kingdom;

    Medical Department I, Saarland University Medical School, D-66421 Homburg, Germany;

    Department of Oncology, University Hospital Zurich, CH-8091 Zurich, Switzerland;

    Department of Oncology, University Hospital Zurich, CH-8091 Zurich, Switzerland;

    Department of Oncology, University Hospital Zurich, CH-8091 Zurich, Switzerland;

    Department of Oncology, University Hospital Zurich, CH-8091 Zurich, Switzerland;

    Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford 0X3 9DS, United Kingdom;

    Department of Oncology, University Hospital Zurich, CH-8091 Zurich, Switzerland;

    Centre for Molecular Medicine and Klinik I fur Innere Medizin, Labor Tumorgenetik, Universitat zu Kbln, 50924 Cologne, Germany;

    Centre for Molecular Medicine and Klinik I fur Innere Medizin, Labor Tumorgenetik, Universitat zu Kbln, 50924 Cologne, Germany;

    Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford 0X3 9DS, United Kingdom;

    Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom;

    Department of Oncology, University Hospital Zurich, CH-8091 Zurich, Switzerland;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号